JUNE 2021 / SEROLOGY

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

		- 1		
NA.	SE2	SE1		
NA. Not Applicable	CRP	RA	Latameter	Daramatar
	Positive	Negative	Result	Your
	66.01 mg/L	Negative 12.61 IU/ml		Your Value
	Positive	Negative	Result	Intended
	Turbidimetry (n-406)	Turbidimetry (n-271)		Method
	70.5501	10.7787	Mean	Robust
	12.1574	4.3006	SD	Robust
	0.76 to 822	0.09 to 133		Range
	-0.4	0.4	score	Z & Z
	2	2	Marks	Max
	2	2	Score	Your

NA: Not Applicable

	SE3		
Syphilis ELISA	ТРНА	RPR/VDRL	Parameter
		Negative	Your Result
		Non-Reactive	Intended result
NOT DONE		4	correct
E			Incorrect
		2	Max Marks
		2	Your Score

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

	E
	MBER
	ID:
	Z
	0
	4
	3
ľ	

		The second second						The same of the same of	The second second	
Maximum marks = 71	Maximum	2	2	2	17	17	19	4	4	4
97.9%	69.5	2	2	2	17	17	18	3.5	4	4
	The same of the sa		State of the last	The second named as well as we	Contract of the last	-	The second second			
Marks obtained	Marks	SE3	SE2	SE1	CU3	CU2	CU1	SM3	SM2	SM1
			The same of the sa	CONTRACTOR OF THE PERSONS	The second second		The Party of the last of the l	Marin San Land and Street Stre		

Dr. Rani Diana Sahni Scientific Co-ordinator

Report Dispatch Date:30.10.2021

Dr. John A Jude Prakash Quality Manager

****************** End of Report ************

G. S. Or Ord

Dr. V. Balaji PT Co-ordinator

FINAL IDENTIFICATION: Proteus mirabilis			<u>Disclaimer:</u>
Identification details	Reported	Not reported	Evaluation (7 marks)
Microscopy (Gram stain + Motility)	✓		0 0.5 1
Salient culture and biochemical findings enabling final dentification	✓		1 2 3 4
Minimum 3 key characteristics) Final identification	√		0 0.5 1 1.5 (2

Susceptibility report		EXPECTED	REPORT	PARTICIPA	ANT REPORT	MARK	TYPE OF ERROR
	Zone size (mm)	MIC (μg/ml)	Interpretation	Correct	Incorrect	10 marks	Error
Co-trimoxazole	≥16	≤2/38	Susceptible	1		-1 0 1 (2)	mE/ME/VME
Levofloxacin	≥21	≤0.5	Susceptible	/		-1 0 1 (2)	mE/ME/VME
Piperacillin- Tazobactam	≥21	≤16	Susceptible	/		-1 0 1 2	mE/ME/VME
Ertapenem	≥22	≤0.5	Susceptible	/		-1 0 1 (2)	mE/ME/VME
Meropenem	≥23	≤1.0	Susceptible	/		-1 0 1 (2)	mE/ME/VME

DECEMBER 2020 / SEROLOGY

Please refer the attached evaluation format/answer template for details on the criteria for evaluation

	Parameter	Your Result	Your Value		Intend Resu	led	Method	Robust Mean	Robust SD	Range (mg/L)	Z & Z' score	Max Marks	Your Score
SE1	RA	Negative	12.20 IU/mL		Negati	ve	Turbidimetry (n-245)	8.5538	4.1086	0.0 to 31.260	0.9	2	2
SE2	WIDAL*	Correct	Correct	STO Negative		Interpretation Negative	Slide agglutination		Not Appl		2	2	
SE3	CRP	Positive	67.13 mg/L		Positiv	e	Turbidimetry (n-330)	60.0593	10.4966	0.08 to 199.9	0.7	2	2

RA: Rheumatoid Factor, CRP: C-reactive Protein. NA: Not Applicable. *Expected value is determined by the Proficiency Testing Provider (PTP).

Page 4 of 5

OCTOBER 2021 / SEROLOGY

Please refer the attached evaluation format/answer template for details on the criteria for evaluation.

		Your Inter	pretation		Intend	led Result	Max Marks	Your
Par	rameter	Correct	Incorrect	STO	STH	Interpretation	Max Marks	Score
SE1	Widal*	1		Negative	Negative	Not Suggestive of Enteric Fever / Typhoid Fever	2	2

*Expected value is determined by the Proficiency Testing Provider (PTP).

	Parameter	Your Result	Your Value	Intended Result	Method	Robust Mean	Robust SD	Range	Z & Z' score	Max Marks	Your Score
SE2	ASO	Negative	Not Reported	Negative	Latex Agglutination (n-450)		Not Appl	icable		2	2
SE3	CRP	Positive	68.23 mg/L	Positive	Turbidimetry (n-415)	76.8130	13.8291	0.043 to 987	-0.6	2	2

Disclaimer:

This is a confidential document and subject to the rules of confidentiality as described by the ISO 17043:2010 standard.

MEMBER ID:	M	0	4	3	3
		_	_	_	10

WIDEK ID.		SM3	CU1	CU2	CU3	SE1	SE2	SE3	Marks	obtained
SM1	SM2 4	4	17	17	19	2	2	2	71	100%
4	4	4	17	17	19	2	2	2	Maximum	n marks = 71

Town and Dr. Rani Diana Sahni

Scientific Co-ordinator

Report Dispatch Date: 15.03.2022

Dr. John A Jude Prakash Quality Manager

v. Baran Dr. V. Balaji PT Co-ordinator

Page 6 of 6